Genetic variants of p21 and p27 and hepatocellular cancer risk in a Chinese Han population: A case-control study

International Journal of Cancer

Volumn 132, Issue 9, 2013, Pages 2056-2064

  Liu, Fei ^a   Wei, Yong Gang ^a   Luo, Li Mei ^a   Wang, Wen Tao ^a   Yan, Lv Nan ^a   Wen, Tian Fu ^a   Xu, Ming Qing ^a   Yang, Jia Yin ^a   Li, Bo ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

case control study; CDKN1A; CDKN1B; hepatocellular carcinoma susceptibility; polymorphism

Indexed keywords

ALPHA FETOPROTEIN; ARGININE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HEPATITIS B SURFACE ANTIGEN; SERINE; VALINE;

ADULT; ARTICLE; BLOOD SAMPLING; CATALYSIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CHINESE; CHINESE HAN; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILY HISTORY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TUMOR VOLUME;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84874116432     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27885     Document Type: Article

References (48)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Farazi PA, Depinho RA,. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev 2006; 6: 674-87.
3. Yuen MF, Hou JL, Chutaputti A,. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-53.
4. Parkin DM,. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
5. Aravalli RN, Steer CJ, Cressman EN,. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-63.
6. Chen CJ, Chen DS,. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology 2002; 36: 1046-9.
7. Nissen NN, Martin P,. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 2002; 35 (5 Suppl 2): S79-S85.
8. Bowen DG, Walker CM,. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946-52.
9. Hartwell LH, Kastan MB,. Cell cycle control and cancer. Science 1994; 266: 1821-8.
10. Sherr CJ,. Cancer cell cycles. Science 1996; 274: 1672-7.
11. Abukhdeir AM, Park BH,. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008; 10: e19.
12. Schor E, da Silva ID, Sato H, et al. P27Kip1 is down-regulated in the endometrium of women with endometriosis. Fertil Steril 2009; 91: 682-6.
13. Shiohara M, el-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-4.
14. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995; 55: 2266-9.
15. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231-4.
16. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-30.
17. Jiang M, Shao ZM, Wu J, et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997; 74: 529-34.
18. Shi YZ, Hui AM, Takayama T, et al. Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer 2000; 83: 50-5.
19. Mori M, Mimori K, Shiraishi T, et al. p27 expression and gastric carcinoma. Nat Med 1997; 3: 593.
20. Mousses S, Ozcelik H, Lee PD, et al. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 1995; 4: 1089-92.
21. Sjalander A, Birgander R, Rannug A, et al. Association between the p21 codon 31 A1(Arg) allele and lung cancer. Hum Hered 1996; 46: 221-5.
22. Cave H, Martin E, Devaux I, et al. Identification of a polymorphism in the coding region of the p27Kip1 gene. Ann Genet 1995; 38: 108.
23. Chang BL, Zheng SL, Isaacs SD, et al. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 2004; 64: 1997-9.
24. Tomoda K, Kubota Y, Kato J,. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999; 398: 160-5.
25. Ma H, Jin G, Hu Z, et al. Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women. Int J Cancer 2006; 119: 2173-8.
26. Chen J, Amos CI, Merriman KW, et al. Genetic variants of p21 and p27 and pancreatic cancer risk in non-Hispanic Whites: a case-control study. Pancreas 2010; 39: 1-4.
27. Wang Z, Sturgis EM, Zhang F, et al. Genetic variants of p27 and p21 as predictors for risk of second primary malignancy in patients with index squamous cell carcinoma of head and neck. Mol Cancer 2012; 11: 17.
28. Shih CM, Lin PT, Wang HC, et al. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 2000; 91: 9-15.
29. Liu B, Zhang Y, Jin M, et al. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog 2010; 49: 75-84.
30. Yang W, Qi Q, Zhang H, et al. p21 Waf1/Cip1 polymorphisms and risk of esophageal cancer. Ann Surg Oncol 2010; 17: 1453-8.
31. Waga S, Hannon GJ, Beach D, et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369: 574-8.
32. Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
33. Choi HR, Tucker SA, Huang Z, et al. Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis. Int J Oncol 2003; 22: 409-14.
34. Koufos A, Grundy P, Morgan K, et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 1989; 44: 711-9.
35. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. Clin Oncol 1999; 17: 3150-9.
36. Hui AM, Kanai Y, Sakamoto M, et al. Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997; 25: 575-9.
37. Hui AM, Sun L, Kanai Y, et al. Reduced p27Kip1 expression in hepatocellular carcinomas. Cancer Lett 1998; 132: 67-73.
38. Lukas J, Groshen S, Saffari B, et al. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 1997; 150: 167-75.
39. Huppi K, Siwarski D, Dosik J, et al. Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). Oncogene 1994; 9: 3017-20.
40. Sherr CJ, Roberts JM,. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
41. Mousses S, Ozcelik H, Lee PD, et al. Two variants of the CIP/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 1995; 4: 1089-92.
42. Kibel AS, Suarez BK, Belani J, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003; 63: 2033-6.
43. Figueiredo JC, Knight JA, Cho S, et al. Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. BMC Cancer 2007, 7: 99.
44. Nakamura N, Ramaswamy S, Vazquez F, et al. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000; 20: 8969-82.
45. Millard SS, Vidal A, Markus M, et al. A U-rich element in the 5′ untranslated region is necessary for the translation of p27 mRNA. Mol Cell Biol 2000; 20: 5947-59.
46. Kullmann M, Gopfert U, Siewe B, et al. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′UTR. Genes Dev 2002; 16: 3087-99.
47. Wang XW, Gibson MK, Vermeulen W, et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995; 55: 6012-6.
48. Furutani M, Arii S, Tanaka H, et al. Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma. Cancer Lett 1997; 111: 191-7.